Cover Image

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer

Saved in:

Bibliographic Details
Main Author:	Ji Ruan (Author)
Format:	Book
Published:	Elsevier, 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer
by: Lijie Sima, et al.
Published: (2024)

Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
by: Chao-Yue Sun, et al.
Published: (2018)

Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer
by: Yueqin Wang, et al.
Published: (2023)

Targeting slug-mediated non-canonical activation of c-Met to overcome chemo-resistance in metastatic ovarian cancer cells
by: Linlin Chang, et al.
Published: (2019)

Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
by: Juan Bautista Blaquier, et al.
Published: (2022)

MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features
by: Lisi Yuan, et al.
Published: (2023)

Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
by: Ji F, et al.
Published: (2015)

MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases
by: Shirong Ma, et al.
Published: (2018)

STUDENTS' PERSPECTIVES ON ONLINE LEARNING - ARE THEIR EXPECTATIONS MET BY CURRENT TEACHING PRACTICES?
by: Iulia GONŢA, et al.
Published: (2021)

ROS-1 re-arrangements and c-MET amplifications in adenocarcinoma lung: A tertiary care center study from North India
by: Saumya Shukla, et al.
Published: (2019)

Identificatie met Nederland
by: Wetenschappelijke Raad voor het Regeringsbele
Published: (2007)

'Aurelleterapie' met geestesvertraagdes
by: N.M.E. de Bruto
Published: (1980)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
by: Nam Ah Kim, et al.
Published: (2020)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
by: El Darsa H, et al.
Published: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer
by: Ling Lim, et al.
Published: (2019)

Fairies I Have Met
by: Stawell, Rodolph, Mrs., 1865-1949; Dulac, Edmund, 1882-1953 [Illustrator]

The people I've met
by: Mirosława Nowak-Dziemianowicz
Published: (2014)

Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells' Invasive Abilities
by: Aleksandra Simiczyjew, et al.
Published: (2019)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
by: Huang L, et al.
Published: (2020)

Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
by: Pengyun Li, et al.
Published: (2023)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
by: Zhuo-Xun Wu, et al.
Published: (2022)

Roles of MET in Cancer Development and Treatment
Published: (2023)

Chapter In gesprek met Iris Kensmil
by: Kensmil, Iris
Published: (2023)

Bears I Have Met—and Others
by: Kelly, Allen, 1855-1916

Chapter In gesprek met Iris Kensmil
by: Kensmil, Iris
Published: (2023)

The MET Oncogene: An Update on Targeting Strategies
by: Simona Gallo, et al.
Published: (2024)

Expression of c-MET in Invasive Meningioma
by: Sumi Yun, et al.
Published: (2015)

Klankontwikkeling van baby's met gehoorverlies
by: Lizet Ketelaar, et al.
Published: (2021)

Exploring the potential of small molecules of dual c-Met and VEGFR inhibitors for advances and future drug discovery in cancer therapy
by: Sachin A. Dhawale, et al.
Published: (2024)

Liquid Biopsy in <i>EGFR</i>-Mutated Advanced NSCLC from T790M to <i>MET</i> Amplification: Clinical Implications and Possibilities in the Resistance Setting
by: Luigi Della Gravara, et al.
Published: (2023)

Thuis voorlezen met digitale prentenboeken Een veelbelovende interventie voor twee- en driejarigen met een taalachterstand?
by: Bus, Adriana
Published: (2020)

Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy
by: Yan Zhang, et al.
Published: (2020)

Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth
by: Rameswari Chilamakuri, et al.
Published: (2024)

The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance
by: Zhenchao Liu, et al.
Published: (2024)

Activated O2•− and H2O2 Mediated Cell Survival in SU11274-Treated Non-Small-Cell Lung Cancer A549 Cells via c-Met-PI3K-Akt and c-Met-Grb2/SOS-Ras-p38 Pathways
by: Ying Liu, et al.
Published: (2012)

Component 1 Inhibitor Missense (Val480Met) Variant Is Associated With Gene Expression and Sepsis Development in Neonatal Lung Disease
by: Enas F. Elngar, et al.
Published: (2022)

Ghosts I Have Met and Some Others
by: Bangs, John Kendrick, 1862-1922

Kijk op en contacten met buitenlanders
by: Esveldt, I.
Published: (2001)

Fraude met belastingen, subsidies en premies
by: Godschalk, J.J
Published: (1988)